SPR Therapeutics, LLC

36 articles about SPR Therapeutics, LLC

• SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System

  2/1/2024

  SPR Therapeutics announced that it has secured $85 million in financing including $25 million in Series D-1 insider equity and a $60 million debt facility.

• SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024

  1/16/2024

  SPR Therapeutics, Inc. will be featured prominently at the North American Neuromodulation Society Annual Meeting January 18-21 in Las Vegas.

• SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT® PNS System for Low Back Pain

  12/12/2023

  SPR Therapeutics, Inc. announced the final patient was enrolled in the RESET Clinical Trial of SPRINT® PNS for the treatment of chronic low back pain.

• SPR Therapeutics Announces 20,000th Patient Implant of SPRINT® PNS System

  8/22/2023

  SPR® Therapeutics announced the 20,000th patient implant of the SPRINT® PNS System.

• SPR Therapeutics Named a Top Workplace for Second Consecutive Year

  6/25/2023

  SPR Therapeutics has been selected as a Top Workplaces honoree for the second year in a row by cleveland.com and The Plain Dealer.

• New SPRINT extensa XT™ System with Bimodal PNS™ Offers Synergistic Treatment of Pain

  4/25/2023

  SPR® Therapeutics announced the introduction of the SPRINT extensa XT System with bimodal peripheral nerve stimulation (PNS), designed to deliver a comprehensive approach to the alleviation of pain by treating dual nerve targets with synergistic stimulation modalities.

• SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System

  2/3/2023

  SPR Therapeutics announced it has obtained clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling, which increases the intended patient population of the SPRINT® PNS System, along with new advances to enhance and simplify the SPRINT PNS System’s lead securement mechanism.

• Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves

  9/21/2022

  SPR Therapeutics shared data on the use of peripheral nerve stimulation to deliver pain relief for patients suffering from axial neck pain at the Pacific Spine Pain Society annual meeting in Las Vegas.

• Next Generation MicroLead 2.0 Now Available with the SPRINT® PNS System

  9/6/2022

  SPR Therapeutics announced the formal introduction of its new MicroLead™ 2.0, designed to enhance the performance of the SPRINT® PNS System.

• Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs

  8/2/2022

  SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs.

• Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results

  5/6/2022

  SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation in the management of chronic pain.

• Prolonged Temporary Neurostimulation Treatment Period Offered by the SPRINT® PNS System May Optimize Pain Management Care Pathway While Reducing Healthcare Costs

  3/15/2022

  SPR Therapeutics announced publication of a study in the Journal of Pain Research demonstrating how a longer initial treatment period may better identify neurostimulation responders and non-responders in contrast to a conventional, brief trial period or no trial at all.

• 

  Money on the Move: October 13 – 19

  10/20/2021

  Investors can take their pick of life sciences companies, with more innovative ideas and treatments being added to pipelines daily. Here's who brought in the sheaves this week.

• SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System– Expanding U.S. Commercial Team Amid Record-Breaking Growth –

  10/18/2021

  SPR Therapeutics announced today it has raised $37 million in an oversubscribed Series D growth equity financing.

• SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFAResults Highlight Clinically Significant and Durable Reductions in Chronic Low Back Pain Following Treatment

  3/2/2021

  SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of percutaneous peripheral nerve stimulation for patients with recurrent low back pain who underwent a radiofrequency ablation procedure at least six months prior.

• SPR Therapeutics Announces 1000th Sprint PNS ProcedureThe SPRINT PNS System is designed to provide sustained pain relief without a permanent implant

  12/4/2019

  The SPRINT PNS System is the only percutaneous PNS device FDA-cleared for the treatment of both chronic and acute pain, and the only PNS system that does not require permanent implantation.

• 

  FDA Clears SPR Therapeutics’ Non-Opioid Neurostimulation Pain Therapies

  8/21/2018

  The U.S. Food and Drug Administration (FDA) cleared Cleveland-based SPR Therapeutics’ SPRINT endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation (PNS) Systems for controlling pain.

• Cleveland's SPR Therapeutics Snags $25 Million in Series C Funding Round

  9/12/2017

• SPR Therapeutics Promotes Dr. Joseph Boggs To SVP Of Research And Development

  9/7/2017

• SPR Therapeutics Awarded $6 Million Contract From The United States Department Of Defense To Advance Non-Opioid Pain Relief Therapy

  5/15/2017